

Independent Assurance Report to Pfizer Inc.

ERM Certification & Verification Services Incorporated (“ERM CVS”) was engaged by Pfizer Inc. (“Pfizer”) to provide limited and reasonable assurance in relation to the selected information set out below and presented on Pfizer’s 2023 Key Performance Indicators (the “Disclosure”).

Engagement summary	
Scope of our assurance engagement	<p>Whether the 2023 data for the following key performance indicators are fairly presented in the Disclosure, in all material respects, with the reporting criteria.</p> <ul style="list-style-type: none"> • Total Scope 1 GHG emissions [mt CO₂e] • Total Scope 2 (location-based) GHG emissions [mt CO₂e] • Total Scope 2 (market-based) GHG emissions [mt CO₂e] • GHG intensity [mt CO₂e per million \$ revenue] * • Total Scope 3 GHG emissions from all reported categories (Categories 1, 2, 3, 4, 5, 6, 7, 8, and 15) [mt CO₂e] AND the following individual categories: <ul style="list-style-type: none"> ○ Category 1 - Purchased goods and services; ○ Category 2 – Capital goods ○ Category 3 - Fuel- and energy-related activities; ○ Category 4 - Upstream transportation and distribution; ○ Category 6 - Business travel ○ Category 15 - Investments • Renewable electricity/electricity consumption [%] • Water withdrawal (including non-contact cooling water) [million cubic meters] • Water discharge [million cubic meters] • Water consumption [million cubic meters] • Hazardous waste generated [thousand metric tonnes] • Hazardous waste diverted from disposal [thousand metric tonnes] • Hazardous waste disposed [thousand metric tonnes] <p>Our assurance engagement does not extend to information in respect of earlier periods or to any other information included in the Disclosure.</p> <p><i>* We place reliance on the financial assurance conducted on dollars of revenue as they are presented in the 2023 10-K filing.</i></p>
Reporting period	1 January 2023 to 31 December 2023
Reporting criteria	<ul style="list-style-type: none"> • Pfizer’s GHG Emissions Calculation Methodology, as disclosed here. • Pfizer’s Waste and Water Calculation Methodology, as disclosed here. • The GHG Protocol Corporate Accounting and Reporting Standard (WBCSD/WRI Revised Edition 2015) for Scope 1 and Scope 2 GHG emissions • GHG Protocol Scope 2 Guidance (An amendment to the GHG Protocol Corporate Standard (WRI 2015) for Scope 2 GHG emissions • The Corporate Value Chain Accounting and Reporting Standard (WBCSD/WRI 2011) for Scope 3 GHG emissions
Assurance standard and level of assurance	<p>We performed a limited and reasonable assurance engagement, in accordance with the International Standard on Assurance Engagements ISAE 3000 (Revised) ‘Assurance Engagements other than Audits or Reviews of Historical Financial Information issued by the International Auditing and Assurance Standards Board.</p> <p>Reasonable assurance</p> <ul style="list-style-type: none"> • Total Scope 1 GHG emissions [mt CO₂e] • Total Scope 2 (market- and location-based) GHG emissions [mt CO₂e] <p>Limited assurance</p> <ul style="list-style-type: none"> • All other scopes set out under ‘Scope of our assurance engagement’, above.
Respective responsibilities	<p>Pfizer is responsible for preparing the Disclosure and for the collection and presentation of the information within it, and for the designing, implementing, and maintaining of internal controls relevant to the preparation and presentation of the Disclosure.</p> <p>ERM CVS’ responsibility is to provide conclusions to Pfizer on the agreed scope based on our engagement terms with Pfizer, the assurance activities performed and exercising our professional judgement. We accept no responsibility, and deny any liability, to any party other than Pfizer for the conclusions we have reached.</p>

Our opinion

In our opinion, the 2023 Total Scope 1 and Total Scope 2 (market- and location-based) GHG emissions are fairly presented in the Disclosure, in all material respects, in accordance with the reporting criteria.

Our conclusion

Based on our activities, as described below, nothing has come to our attention to indicate that the key performance indicators, as listed under 'Scope of our assurance engagement' above, except for Total Scope 1 and Total Scope 2 (market- and location-based) GHG emissions, are not fairly presented in the Disclosure, in all material respects, with the reporting criteria.

Our assurance activities

Considering the risk of material misstatement in the Disclosure and the key performance indicators, a multi-disciplinary team of sustainability and assurance specialists performed a range of procedures that included, but were not restricted to, the following:

- Evaluating the appropriateness of the reporting criteria used for the selected information;
- Interviewing senior management representatives responsible for managing the selected information;
- Evaluating relevant reporting systems and processes (including internal control processes);
- Reviewing quantitative and qualitative evidence supporting the reported information;
- Performing an analytical review of the 2023 data for the KPIs, which included testing the completeness and mathematical accuracy of conversions and calculations, and consolidation in line with the stated reporting boundary;
- Conducting visits to a risk-based selection of four in-person visits (Algete, Spain; Newbridge Ireland; Pearl River, USA; Ringaskiddy, Ireland) and four virtual visits (Andover, USA; Brandon, Canada; Tuas, Singapore; Vizag, India) to Pfizer facilities to review systems and source data;
- Reviewing the presentation of the assured information to ensure consistency with our findings; and
- Reviewing the line adjustments regarding non-contact cooling water discharges that resulted in updates to the total water discharge and total water consumption in the KPI Table published in August 2024.

The limitations of our engagement

The reliability of the assured information is subject to inherent uncertainties, given the available methods for determining, calculating, or estimating the underlying information. It is important to understand our assurance conclusions in this context.

Our independence, integrity, and quality control

ERM CVS is an independent certification and verification body accredited by UKAS to ISO 17021:2015. Accordingly, we maintain a comprehensive system of quality control, including documented policies and procedures regarding compliance with ethical requirements, professional standards, and applicable legal and regulatory requirements. Our quality management system is at least as demanding as the relevant sections of ISQM-1 and ISQM-2 (2022).

ERM CVS applies a Code of Conduct and related policies to ensure that its employees maintain integrity, objectivity, professional competence, and high ethical standards in their work. Our processes are designed and implemented to ensure that the work we undertake is objective, impartial and free from bias and conflict of interest. Our certified management system covers independence and ethical requirements that are at least as demanding as the relevant sections of the IESBA Code relating to assurance engagements.

ERM CVS has extensive experience in conducting assurance on environmental, social, ethical and health and safety information, systems, and processes, and provides no consultancy-related services to Pfizer in any respect.



Andrea Duque
Partner, Corporate Assurance
Malvern, PA

19 September 2024

On behalf of
ERM Certification & Verification Services Incorporated
www.ermcvs.com | post@ermcvs.com

